OHR PHARMACEUTICAL INC.
|OHR PHARMACEUTICAL INC. Patent applications|
|Patent application number||Title||Published|
|20150099727||Aminosteroids for the Treatment of a PTP1B Associated Disease - This application is directed to the use of aminosteroid compounds for the selective inhibition of the enzyme PTP1B in a mammal for the treatment of diabetes.||04-09-2015|
|20130338069||Preparation of a Therapeutic Composition - A pharmaceutical composition includes a peptide nucleotide composition including Peptide A and Peptide B. Peptide A may be characterized by having SEQ. ID NO: 1. Peptide A may also be characterized by including 31 amino acids lacking any cysteine-cysteine cross links and including six spaced-out proline residues and four glutamine residues. Peptide B may be characterized by having SEQ. ID NO: 2. Peptide B may also be characterized by including 21 amino acids attached at a seine residue in position 18 to a diadenine (3′-5′) diribonecleotide through a diphosphodiester linkage at the 3′-position.||12-19-2013|
|20130281420||Ophthalmic Formulations of Squalamine - The invention relates to ophthalmic formulations of squalamine or its pharmaceutically acceptable salts for the treatment of conditions of the eye such as, for example, wet age-related macular degeneration (wet AMD), choroidal neovascularization, retinopathy, dry age-related macular degeneration (dry AMD), polypoidal choroidal vasculopathy, neovascularization following ocular surgery, macular edema, retinal venous occlusion, subchoroidal neovascularization, retinal epithelial detachment, pterygum or foveal geographic atrophy of the retinal pigment epithelium.||10-24-2013|
|20120271032||Preparation of a Therapeutic Composition - Product R, a novel therapeutic composition for treating viral infections and stimulating the immune system comprises a unique peptide having 31 amino acids and another unique peptide having 21 amino acids and connected with an oligo-nucleotide through a diphosphodiester or diphosphodithioate ester linkage. The composition has a light absorption spectrum with typical absorption ratios of 1.998 at 260 mn/280 nm and 1.359 at 260 nm/230 nm.||10-25-2012|
Patent applications by OHR PHARMACEUTICAL INC.